PMC:7195088 / 62441-62831
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1859 | 281-299 | Gene | denotes | C-reactive protein | Gene:1401 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T104 | 127-131 | Body_part | denotes | body | http://purl.org/sig/ont/fma/fma256135 |
| T105 | 172-177 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
| T106 | 227-237 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
| T107 | 292-299 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T50 | 172-177 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T343 | 21-25 | http://purl.obolibrary.org/obo/CLO_0008416 | denotes | peer |
| T344 | 21-25 | http://purl.obolibrary.org/obo/CLO_0050081 | denotes | peer |
| T345 | 111-112 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T346 | 160-161 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
| T347 | 172-177 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| T348 | 172-177 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T28602 | 82-93 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T88075 | 292-299 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T451 | 0-390 | Sentence | denotes | In their still-to-be-peer-reviewed case series, the following were observed after tocilizumab administration: (a) reduction in body temperature (21/21, 100%); (b) improved blood oxygenation (15/21, 71.4%); (c) normalization of lymphocyte count (10/17, 58.8%); (d) normalization of C-reactive protein (16/19, 82.4%); and (c) resolution of abnormalities on computed tomography (19/21, 90.5%). |